Xosomix (pronounced as "exosomix") is a biotechnology company involved in the development of the next generation therapeutics using exosomes. Xosomix is founded on the preclinical research demonstrating the first therapeutic use of exosomes in a brain disorder, Rett Syndrome.

Problem: About 20% of the U.S. population suffers from a diagnosable mental illness. Brain disorder therapeutics is ~$100B market with just 50% patient reach and poised to grow at a rapid rate. Despite huge market and unmet need, the drugs targeting brain disorders range from ineffective to partially effective and treat symptoms rather than altering the course of disease. In addition, early diagnosis of neurological disorders remains a challenge and severely limits the window and scope of intervention for the development of therapeutics. 

Solution: Exosomes are transportation logistics services of the body that can cross blood-brain barrier (BBB) to carry biomolecules to specific cellular targets and have capability to heal the defective cells and tissues. Exosomes play a fundamental role in the neural circuit development. Exosomes are part of endolysosomal system and are emerging as a key player in the progression of neurodegenerative disorders. Their therapeutic potential has been demonstrated in pre-clinical models of stroke and Rett Syndrome, a neurodevelopmental disorder with autism like symptoms. We will harness the brain delivery capability of exosomes to enable use drugs that failed due to poor BBB penetration and increase the efficacy of existing drugs. We will use state of the art proteomic platform to discover the early biomarkers of neurological disorders on CNS-derived exosomes from the blood. We will harness the healing capability of exosomes to usher the next generation of therapeutics for brain disorders.

Xosomix

Org chart

Teams

Offices